BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 34337998)

  • 1. Payer perceptions of the use of real-world evidence in oncology-based decision making.
    Brixner D; Biskupiak J; Oderda G; Burgoyne D; Malone DC; Arondekar B; Niyazov A
    J Manag Care Spec Pharm; 2021 Aug; 27(8):1096-1105. PubMed ID: 34337998
    [No Abstract]   [Full Text] [Related]  

  • 2. Payer perceptions on the use of patient-reported outcomes in oncology decision making.
    Oderda G; Brixner D; Biskupiak J; Burgoyne D; Arondekar B; Deal LS; Quek RG; Niyazov A
    J Manag Care Spec Pharm; 2022 Feb; 28(2):188-195. PubMed ID: 34806908
    [No Abstract]   [Full Text] [Related]  

  • 3. Payer perceptions on the use of economic models in oncology decision making.
    Biskupiak J; Oderda G; Brixner D; Burgoyne D; Arondekar B; Niyazov A
    J Manag Care Spec Pharm; 2021 Nov; 27(11):1560-1567. PubMed ID: 34714111
    [No Abstract]   [Full Text] [Related]  

  • 4. Is Real-World Evidence Used in P&T Monographs and Therapeutic Class Reviews?
    Hurwitz JT; Brown M; Graff JS; Peters L; Malone DC
    J Manag Care Spec Pharm; 2020 Dec; 26(12):1604-1611. PubMed ID: 33251991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is Real-World Evidence Used in P&T Monographs and Therapeutic Class Reviews?
    Hurwitz JT; Brown M; Graff JS; Peters L; Malone DC
    J Manag Care Spec Pharm; 2017 Jun; 23(6):613-620. PubMed ID: 28530524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Online tools to synthesize real-world evidence of comparative effectiveness research to enhance formulary decision making.
    Chen S; Graff J; Yun S; Beal B; Ta JT; Bansal A; Carlson JJ; Veenstra DL; Basu A; Devine B
    J Manag Care Spec Pharm; 2021 Jan; 27(1):95-104. PubMed ID: 33377442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Payer Perspectives on Patient-Reported Outcomes in Health Care Decision Making: Oncology Examples.
    Brogan AP; DeMuro C; Barrett AM; D'Alessio D; Bal V; Hogue SL
    J Manag Care Spec Pharm; 2017 Feb; 23(2):125-134. PubMed ID: 28125369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of Real-World Evidence in US Payer Coverage Decision-Making for Next-Generation Sequencing-Based Tests: Challenges, Opportunities, and Potential Solutions.
    Deverka PA; Douglas MP; Phillips KA
    Value Health; 2020 May; 23(5):540-550. PubMed ID: 32389218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Evidence: Useful in the Real World of US Payer Decision Making? How? When? And What Studies?
    Malone DC; Brown M; Hurwitz JT; Peters L; Graff JS
    Value Health; 2018 Mar; 21(3):326-333. PubMed ID: 29566840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing-Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative.
    Orsini LS; Berger M; Crown W; Daniel G; Eichler HG; Goettsch W; Graff J; Guerino J; Jonsson P; Lederer NM; Monz B; Mullins CD; Schneeweiss S; Brunt DV; Wang SV; Willke RJ
    Value Health; 2020 Sep; 23(9):1128-1136. PubMed ID: 32940229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of the Level of Satisfaction and Unmet Data Needs for Specialty Drug Formulary Decisions in the United States.
    Choi Y; Navarro RP
    J Manag Care Spec Pharm; 2016 Apr; 22(4):368-75. PubMed ID: 27023690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preapproval Information Exchange: Perspectives of U.S. Population Health Decision Makers on Preferences for Early Engagement with Investigational Therapies.
    Brixner D; Woodward TC; Seifter N; Biskupiak J; Marciniak M; Neumann P; Oderda G
    J Manag Care Spec Pharm; 2019 Feb; 25(2):164-173. PubMed ID: 30698089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging trends in cancer care: health plans' and pharmacy benefit managers' perspectives on changing care models.
    Greenapple R
    Am Health Drug Benefits; 2012 Jul; 5(4):242-53. PubMed ID: 24991323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving transparency to build trust in real-world secondary data studies for hypothesis testing-Why, what, and how: recommendations and a road map from the real-world evidence transparency initiative.
    Orsini LS; Monz B; Mullins CD; Van Brunt D; Daniel G; Eichler HG; Graff J; Guerino J; Berger M; Lederer NM; Jonsson P; Schneeweiss S; Wang SV; Crown W; Goettsch W; Willke RJ
    Pharmacoepidemiol Drug Saf; 2020 Nov; 29(11):1504-1513. PubMed ID: 32924243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of real-world evidence for oncology clinical decision making in emerging economies.
    Petracci F; Ghai C; Pangilinan A; Suarez LA; Uehara R; Ghosn M
    Future Oncol; 2021 Aug; 17(22):2951-2960. PubMed ID: 34044583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration.
    Chan K; Nam S; Evans B; de Oliveira C; Chambers A; Gavura S; Hoch J; Mercer RE; Dai WF; Beca J; Tadrous M; Isaranuwatchai W
    BMJ Open; 2020 Jan; 10(1):e032884. PubMed ID: 31915169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Schizophrenia population health management: perspectives of and lessons learned from population health decision makers.
    Roach M; Lin D; Graf M; Pednekar P; Chou JW; Benson C; Doshi JA
    J Manag Care Spec Pharm; 2021 Oct; 27(10-a Suppl):S2-S13. PubMed ID: 34652218
    [No Abstract]   [Full Text] [Related]  

  • 19. Real-World Evidence: Bridging Gaps in Evidence to Guide Payer Decisions.
    Roberts MH; Ferguson GT
    Pharmacoecon Open; 2021 Mar; 5(1):3-11. PubMed ID: 32557235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advancing a managed care pharmacy research agenda: Generating real-world evidence to support US Food and Drug Administration Accelerated Approvals and improving benefit design to address health inequities.
    Brixner D; Couto J; Worley K; Small A; Panchal R; Dharbhamalla V; Eichenbrenner P
    J Manag Care Spec Pharm; 2022 Aug; 28(8):911-917. PubMed ID: 35722828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.